Shelter Pharma (543963) Q4 17/18 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 17/18 earnings summary
23 Oct, 2026Executive summary
FY18 revenue from operations was ₹314.64m versus ₹300.07m in FY17; net profit rose to ₹544,408 from ₹473,302.
Business remained focused on manufacturing Ayurvedic and veterinary medicines; directors cited continued efforts to identify future growth opportunities in the pharmaceutical industry.
Financial highlights
Revenue from operations was ₹314.64m in FY18 versus ₹300.07m in FY17; total income was ₹314.75m versus ₹308.37m.
Profit before tax was ₹689,964 versus ₹606,422; profit after tax was ₹544,408 versus ₹473,302.
Material consumed was ₹291.06m versus ₹281.72m; other expenses were ₹15.40m versus ₹14.77m.
Other income fell to ₹104,602 from ₹8.30m in FY17.
Outlook and guidance
Directors are pursuing avenues for future growth in the pharmaceutical industry; no numerical targets were stated.
Profits were to be retained for future growth; no dividend was recommended for FY18.
Latest events from Shelter Pharma
- Revenue declined, but FY19 net profit and EPS improved; no dividend was recommended.543963
Q4 18/19 - Revenue and PAT rose in FY20 as factory expansion advanced; Rs 3 crore of advances were written off.543963Q4 19/20
- COVID disruption cut sales as FY21 profit fell; ₹30 lakh of old advances was written off.543963Q4 20/21
- FY22 revenue and profit rose sharply, while COVID disruptions remained a sales risk.543963Q4 21/22
- FY23 profit rose, while receivables climbed and an IPO of up to ₹350m advanced.543963Q4 22/23
- Strong revenue and profit growth, full utilization of raised funds, and clean audit opinion.543963Q4 25/26
- Revenue and profit increased year-over-year, with all raised funds used as intended.543963Q2 25/26
- Revenue and net profit grew year-over-year, with EPS rising to ₹3.06.543963Q2 24/25
- Revenue and net profit rose year-over-year, with robust financials and new auditor appointments.543963Q4 24/25